Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2012-01744 | Registry Identifier | NCI CTRP |
Not provided
Not provided
Not provided
Low Accrual
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary aim of this proposal is to present a novel, multimodal treatment strategy for increasing lean body mass in individuals with cancer who experience cachexia between baseline and day 29 (+/- 3 days). The strategy includes graded resistance training and aerobic exercise, targeted nutrient supplementation and pharmacologic intervention (melatonin).
We postulate that this strategy, together with the simultaneous management of symptoms that decrease appetite (e.g. depression, pain, and nausea), will also accomplish our secondary objectives of improving clinical outcomes such as strength and function between baseline and day 29 (+/- 3 days).
The Study Drugs:
Melatonin is a hormone that helps reduce inflammation and poor food absorption caused by cancer. It may also enhance the effects of ibuprofen.
Juven is a nutritional supplement that is designed to help build muscle and slow muscle breakdown.
Screening Tests:
Before you can start treatment on this study, you will have "screening tests" to help the doctor decide if you are eligible to take part in this study. The following tests will be performed:
Study Drug Administration:
You will take one (1) 20mg capsule of melatonin every night. It can be taken with or without food. It should be taken with 8 ounces (1 cup) of water.
You will drink 90 calories of Juven, twice a day. Juven is a powder supplement that is mixed into 8 ounces of water. It is available in orange or grape flavors.
You will also be instructed to increase your daily calorie intake by at least 1,000 calories. To assist you in doing so, dietary advice will be given to you by a nurse or physician.
Exercise Training:
You will complete 2 exercise training sessions a week. The sessions will combine resistance and graded aerobic training.
Resistance training (with Thera-bands) is designed to increase the muscle-building effects of a hormone called testosterone. Thera-bands are rubber bands that you can hold or put around your feet to provide resistance to your muscles when you bend and flex your arms and legs.
You will be instructed in how to do 3 upper-body exercises (chest press, shoulder press, and arm pull down) and 3 lower-body exercises (leg press, leg extension, and leg flexion).
At your first visit, a physician will educate you to make sure that all exercises are done correctly.
Each repetition will take 12 seconds to complete (6 seconds to bend, then 6 seconds to straighten your arm or leg). When 6 repetitions are completed, the next week's set will be increased by 1 repetition.
Graded aerobic exercise is a walking/running program that may help you exercise longer.
Graded aerobic exercise involves walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate. There will be a 3-minute warm-up and a 3-minute cool-down before and after this exercise.
During your first visit, you will be shown how to monitor your heart rate and how to exercise at 70-80% of your maximum heart rate.
You will add 1 minute to your aerobic exercise at the start of each week.
You will receive your own customized aerobic and resistance exercise program based on your range of motion and risk for falls, which will be evaluated by the study staff.
If you experience chest pain, have a temperature over 100.4 °F, have a platelet count of lower than a certain level, have fresh bruises, or shortness of breath at rest, you will be advised to stop exercising until these are relieved.
Evaluations:
While on study, within 3 days of the days listed below, the following measurements will be monitored:
Length of Study:
You will be on study for 29 days (1 cycle).
This is an investigational study. Melatonin and Juven are commercially available nutritional supplements and are exempt from FDA approval. However, in patients with cancer and cachexia, the study treatment (resistance training, aerobic exercise, and the use of Juven, and melatonin) is considered experimental. At this time, it is only being used in research.
Up to 40 patients will be enrolled on this study. Up to 30 patients will be enrolled at M.D. Anderson, and 10 will be enrolled at the University of Alabama-Birmingham.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Multimodal Treatment Strategy | Experimental | Exercise Program + Pharmacologic Intervention (Melatonin + Atenolol + Ibuprofen) + Nutritional Supplementation (Juven) - Resistance training sessions twice weekly using Thera-bands. Walking or running for 3-4 minutes at 70-80% of maximum predicted heart rate. Melatonin 20 mg by mouth (PO) Daily. 90 calories of Juven, twice a day. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Graded Resistance Training | Behavioral | Resistance training sessions twice weekly using Thera-bands. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Participant Gain in Lean Body Mass | Measure increases in lean body mass in individuals with cancer who experience cachexia between baseline and day 29 (+/- 3 days). | Baseline to Day 29, approximately 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Improvement of Clinical Outcomes | Improvement of clinical outcomes such as strength and function between baseline and day 29 (+/- 3 days). | Baseline to Day 29, approximately 30 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rony Dev, DO | M.D. Anderson Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UT MD Anderson Cancer Center | Houston | Texas | 77030 | United States |
Not provided
| Label | URL |
|---|---|
| MD Anderson Cancer Center | View source |
Not provided
Early termination of the study due to follow-up issues and low recruitment numbers.
Recruitment Period: February 18, 2008 to December 15, 2010. All recruitment done at The University of Texas MD Anderson Cancer Center.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Multimodal Treatment Strategy | Exercise Program + Pharmacologic Intervention (Atenolol + Ibuprofen + Melatonin) + Nutritional Supplementation (Juven) - Resistance training sessions twice weekly using Thera-bands. Walking or running for 3-4 minutes, and Oral Melatonin 20 mg Daily. 90 calories of Juven, twice a day. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Multimodal Treatment Strategy | Exercise Program + Pharmacologic Intervention (Atenolol + Ibuprofen + Melatonin) + Nutritional Supplementation (Juven) - Resistance training sessions twice weekly using Thera-bands. Walking or running for 3-4 minutes, and Oral Melatonin 20 mg Daily. 90 calories of Juven, twice a day. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Participant Gain in Lean Body Mass | Measure increases in lean body mass in individuals with cancer who experience cachexia between baseline and day 29 (+/- 3 days). | Only 3 patients completed the study and were evaluable for analysis, others were unable to follow the study exercise and intervention elements. There were insufficient data points collected to analyze. | Posted | Baseline to Day 29, approximately 30 days |
|
Adverse event data collection from baseline to day 29 (+/- 3 days). Overall collection period: October 24, 2008 to January 24, 2011.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Multimodal Treatment Strategy | Exercise Program + Pharmacologic Intervention (Atenolol + Ibuprofen + Melatonin) + Nutritional Supplementation (Juven) - Resistance training sessions twice weekly using Thera-bands. Walking or running for 3-4 minutes, and Oral Melatonin 20 mg Daily. 90 calories of Juven, twice a day. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Dizziness | Nervous system disorders | CTCAE 3.0 | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Alopecia | Skin and subcutaneous tissue disorders | CTCAE 3.0 | Systematic Assessment |
The sample size of the available data is too small to detect any significant differences.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Rony Dev, DO/Associate Professor, Palliative Care Med | University of Texas (UT) MD Anderson Cancer Center | CR_Study_Registration@mdanderson.org |
Not provided
| ID | Term |
|---|---|
| D002100 | Cachexia |
| D015431 | Weight Loss |
| ID | Term |
|---|---|
| D001836 | Body Weight Changes |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D015444 | Exercise |
| D008550 | Melatonin |
| D001262 | Atenolol |
| D007052 | Ibuprofen |
| ID | Term |
|---|---|
| D009043 | Motor Activity |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Aerobic Exercise | Behavioral | Walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate. |
|
| Melatonin | Drug | 20 mg by mouth (PO) Daily |
|
| Juven | Dietary Supplement | 90 calories of Juven, twice a day. |
|
| Atenolol | Drug | Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate >110 beats/min) or resting energy expenditure (REE) > 110% of predicted. |
|
| Ibuprofen | Drug | Ibuprofen 1200mg/day in three divided doses. |
|
| Lost to Follow-up |
|
| Ineligible |
|
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Units | Counts |
|---|---|
| Participants |
|
| Secondary | Improvement of Clinical Outcomes | Improvement of clinical outcomes such as strength and function between baseline and day 29 (+/- 3 days). | Only 3 patients completed the study and were evaluable for analysis, others were unable to follow the study exercise and intervention elements. There were insufficient data points collected to analyze. | Posted | Baseline to Day 29, approximately 30 days |
|
|
| 7 |
| 15 |
| 10 |
| 15 |
| Dry Mouth | General disorders | CTCAE 3.0 | Systematic Assessment |
|
| Fatigue | General disorders | CTCAE 3.0 | Systematic Assessment |
|
| Fever | General disorders | CTCAE 3.0 | Systematic Assessment |
|
| Gastrointestinal Hemorrhage | Gastrointestinal disorders | CTCAE 3.0 | Systematic Assessment |
|
| Cord Compression | Musculoskeletal and connective tissue disorders | CTCAE 3.0 | Systematic Assessment |
|
| Fracture | Musculoskeletal and connective tissue disorders | CTCAE 3.0 | Systematic Assessment |
|
| Pneumonia | Respiratory, thoracic and mediastinal disorders | CTCAE 3.0 | Systematic Assessment |
|
| Anorexia | Gastrointestinal disorders | CTCAE 3.0 | Systematic Assessment |
|
| Anxiety | Nervous system disorders | CTCAE 3.0 | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | CTCAE 3.0 | Systematic Assessment |
|
| Depressed level of consciousness | Nervous system disorders | CTCAE 3.0 | Systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | CTCAE 3.0 | Systematic Assessment |
|
| Dizziness | Nervous system disorders | CTCAE 3.0 | Systematic Assessment |
|
| Dry mouth | General disorders | CTCAE 3.0 | Systematic Assessment |
|
| Dyspnea | Respiratory, thoracic and mediastinal disorders | CTCAE 3.0 | Systematic Assessment |
|
| Fatigue | General disorders | CTCAE 3.0 | Systematic Assessment |
|
| Headache | Nervous system disorders | CTCAE 3.0 | Systematic Assessment |
|
| Hemorrhage nasal | Vascular disorders | CTCAE 3.0 | Systematic Assessment |
|
| Insomnia | Nervous system disorders | CTCAE 3.0 | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | CTCAE 3.0 | Systematic Assessment |
|
| Neurology (Other) | Nervous system disorders | CTCAE 3.0 | Systematic Assessment |
|
| Oral pain | General disorders | CTCAE 3.0 | Systematic Assessment |
|
| Pain, Muscle | Musculoskeletal and connective tissue disorders | CTCAE 3.0 | Systematic Assessment |
|
| Pain (Other) | General disorders | CTCAE 3.0 | Systematic Assessment |
|
| Peripheral sensory neuropathy | Nervous system disorders | CTCAE 3.0 | Systematic Assessment |
|
| Rash desquamating | Skin and subcutaneous tissue disorders | CTCAE 3.0 | Systematic Assessment |
|
| Syncope vasovagal | Cardiac disorders | CTCAE 3.0 | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | CTCAE 3.0 | Systematic Assessment |
|
Not provided
Not provided
Not provided
| D013851 | Thinness |
| D014363 | Tryptamines |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D050198 | Phenoxypropanolamines |
| D011412 | Propanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
| D020005 | Propanols |
| D000588 | Amines |
| D010666 | Phenylpropionates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |